33 articles about Domain Therapeutics
Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck for M1069 Clinical Development in Immuno-Oncology
Domain Therapeutics, today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors in immuno-oncology, announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO.
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
Domain Therapeutics Raises $42m Series A Financing
Domain Therapeutics announced the closing of a US $42m series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.
Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking
Unique feature of bioSens-All™ technology enables discovery of therapeutics for pathologies linked to GPCR mistrafficking
Domain Therapeutics secures €6 million ($6.7M) debt financing
GPCR company will expand proprietary portfolio and prepare next financing round
Domain Therapeutics and Pr Michel Bouvier (IRIC Montreal) receive the RSRI award for bioSens-All™ project at ADRIQ-RCTi Innovation Prize gala
GPCR biosensor technology, developed via support of CQDM, Merck and Pfizer, recognized as breakthrough approach in GPCR characterization
Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim
Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects
Domain Therapeutics invests in Ermium Therapeutics to develop first-in-class CXCR4 candidate for autoimmune diseases
G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset
Domain Therapeutics appoints Xavier Leroy as chief technology officer
Drug discovery expert will be responsible for developing Domain’s platforms and driving technology-based projects to support Domain’s development and growth
Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.
Domain Therapeutics appoints Sylvie Ryckebusch to board of directors
Seasoned business executive will bring important insights in licensing strategy and contribute to Domain’s next phase of development
European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare next growth phase
Domain Therapeutics announces that it has secured a €3.5M investment from existing shareholder Seventure Partners, to accelerate its next growth phase.
DOMAIN THERAPEUTICS SIGNS A MULTI-TARGET RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH BOEHRINGER INGELHEIM
Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases
Domain Therapeutics And Pfizer Enter Into Collaboration Agreement On bioSensAll
Merck KGaA Release: Company Announces Research Collaboration With Domain Therapeutics In Immuno-Oncology
Domain Therapeutics Grants Alkermes A Non-Exclusive License For Its G Protein-Coupled Receptor BioSens-All Technology
Domain Therapeutics And Medicxi Launch Mavalon Therapeutics, Aimed At Halting The Progression Of Parkinson's Disease
Domain Therapeutics, Université de Montréal, Iricor And McGill University Extend Licensing And Partnership Agreement On G Protein-Coupled Receptor Biosensor Technology
Domain Therapeutics Launches Specific Purpose Vehicle Kaldi Pharma To Harness The Potential Of Its Adenosine Programs